Virus Transport Media for Molecular Testing

Introducing virusPHIX: The SARS-CoV-2 Virus Transport Medium

  • Inactivates SARS-CoV-2 and other viruses & bacteria
  • Stabilises SARS-CoV-2 RNA for at least 14 days at 20°C
  • Suitable for swab and saliva testing
  • Contains no toxic chemicals and safe for home use
  • Optimised in partnership with UK Lighthouse labs for compatibility with automated pipetting robots in high throughput labs (Hamilton, Ortho & Tecan)
  • Different formulations available according to your application (e.g PCR/LAMP)
  • Manufactured in the UK by Rapid Labs

Virus Inactivation

virusPHIX™ has inactivated all tested viruses and bacteria, including SARS-CoV-2, Dengue, Zika, mTb, Vaccinia, Duck Hepatitis B (a surrogate for Human Hepatitis B), Feline Immunodeficiency Virus (a HIV surrogate), Vaccinia and many others. For the full list of viruses & bacteria inactivated by virusPHIX™, please contact us at

Long term stability of RNA viruses

Independent studies have shown stability of SARS-CoV-2 RNA for 33 days at room temperature and 12 month stability of Hepatitis C Virus RNA at 24°C:

Fig 1. Independent study by Qnostics UK demonstrated that virusPHIX+™ stabilises SARS-CoV-2 virus RNA for at least 33 days at 20°C. Sputum samples spiked with SARS-CoV-2 RNA were analysed over 33 days, and the Ct value was compared with virusPHIX+™ treated samples and control (no stabiliser added)

Fig 2. Additional independent study by Qnostics UK demonstrates 12 month stability of Hepatitis C virus when treated with virusPHIX™ and stored at room temperature. The same 2 HCV strains were stable for 6 months when stored at -80°C without virusPHIX™.

The Pasteur Institute successfully transfers their dengue research to a CL2 Laboratory thanks to virusPHIX™ technology

Mosquito host cells were incubated for 5 days before staining with anti-Dengue antibody. No Dengue virus presence was detected. Read the paper here.
The difference in working in a Cat 3 (CL3) vs Cat 2 (CL2) lab can have huge implications from a financial and logistical perspective in addition to the stringent health and safety measures put in place.
Dengue samples were treated with vivoPHIX™ (the precursor to virusPHIX™) and shipped from East Africa to Paris via Dubai at ambient temperature.

The Sanger Institute maps the mosquito immune system using virusPHIX™ technology:

The study published in Science discusses the discovery of new types of mosquito immune cells, including a rare cell type that could be involved in limiting malaria infection, as well as identifying molecular pathways implicated in controlling the malaria parasite.
The Sanger Institute used vivoPHIX™ to enable the fixation, stabilisation and single cell preparation of hemocytes for scRNA-seq (10x Genomics).
vivoPHIX™ is the sister product to virusPHIX™ which offers the same stabilisation and inactivation properties, with the additional properties of enabling single cell analysis.

The Pasteur Institute has successfully demonstrated inactivation of the Zika Virus using virusPHIX™ technology

To determine the ability of vivoPHIX™ (a sister product of virusPHIX, developed for single cell analysis work) to inhibit ZIKV in mosquito tissue sample, ZIKV-infected mosquito midguts were dissected at 6 dpi. Mosquito midguts were then chopped into 3-4 small pieces then transfer into vivoPHIX™ . Samples were then treated at 4 degree Celsius for 30 minutes before infectious virus titration by focus forming assay. All of the mosquito in the untreated group were infected with >50,000 FFU/mosquito midgut, while no viable virus particles could be detected in the vivoPHIX™ treated particles.